JP2018520094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520094A5 JP2018520094A5 JP2017559025A JP2017559025A JP2018520094A5 JP 2018520094 A5 JP2018520094 A5 JP 2018520094A5 JP 2017559025 A JP2017559025 A JP 2017559025A JP 2017559025 A JP2017559025 A JP 2017559025A JP 2018520094 A5 JP2018520094 A5 JP 2018520094A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- seq
- pharmaceutical composition
- composition according
- signaling inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131870A JP2021191755A (ja) | 2015-05-13 | 2021-08-13 | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562161136P | 2015-05-13 | 2015-05-13 | |
| US62/161,136 | 2015-05-13 | ||
| US201562173836P | 2015-06-10 | 2015-06-10 | |
| US62/173,836 | 2015-06-10 | ||
| US201562243457P | 2015-10-19 | 2015-10-19 | |
| US62/243,457 | 2015-10-19 | ||
| PCT/US2016/031999 WO2016183280A1 (en) | 2015-05-13 | 2016-05-12 | Treatment of beta-thalassemia using actrii ligand traps |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131870A Division JP2021191755A (ja) | 2015-05-13 | 2021-08-13 | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520094A JP2018520094A (ja) | 2018-07-26 |
| JP2018520094A5 true JP2018520094A5 (enExample) | 2019-06-20 |
| JP6976859B2 JP6976859B2 (ja) | 2021-12-08 |
Family
ID=57248528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017559025A Expired - Fee Related JP6976859B2 (ja) | 2015-05-13 | 2016-05-12 | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
| JP2021131870A Pending JP2021191755A (ja) | 2015-05-13 | 2021-08-13 | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131870A Pending JP2021191755A (ja) | 2015-05-13 | 2021-08-13 | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180125928A1 (enExample) |
| EP (1) | EP3294320A4 (enExample) |
| JP (2) | JP6976859B2 (enExample) |
| KR (1) | KR102640198B1 (enExample) |
| CN (1) | CN107847562A (enExample) |
| AU (2) | AU2016261913B2 (enExample) |
| CA (1) | CA2985777A1 (enExample) |
| HK (1) | HK1251157A1 (enExample) |
| IL (2) | IL284686B2 (enExample) |
| JO (1) | JOP20160092B1 (enExample) |
| MY (1) | MY189601A (enExample) |
| PH (1) | PH12017502079A1 (enExample) |
| TN (1) | TN2017000468A1 (enExample) |
| TW (2) | TWI814187B (enExample) |
| WO (1) | WO2016183280A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2781222B1 (en) | 2005-11-23 | 2017-08-02 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TWI626945B (zh) | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| JP5912078B2 (ja) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ， インコーポレイテッド | 熱発生性脂肪細胞を増加させるための方法 |
| EP3290439B1 (en) | 2009-06-12 | 2020-09-02 | Acceleron Pharma Inc. | Truncated actriib-fc fusion proteins |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| TWI730949B (zh) | 2014-12-03 | 2021-06-21 | 美商西建公司 | 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途 |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| CN116531490A (zh) | 2016-07-15 | 2023-08-04 | 阿塞勒隆制药公司 | 用于治疗肺高血压的组合物和方法 |
| HUE067225T2 (hu) | 2016-07-27 | 2024-10-28 | Acceleron Pharma Inc | Mielofibrózis kezelésére szolgáló készítmények |
| CN119241685A (zh) | 2016-11-10 | 2025-01-03 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| HUE068733T2 (hu) * | 2017-06-14 | 2025-01-28 | Celgene Corp | Eljárások mieloproliferatív neoplazma-asszociált mielofibrózis anémia kezelésére |
| CN111801112A (zh) | 2017-11-09 | 2020-10-20 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| US12263205B2 (en) | 2018-04-30 | 2025-04-01 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
| WO2019217715A1 (en) | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| EP3873501A4 (en) * | 2018-10-31 | 2022-07-13 | Celgene Corporation | TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN PEOPLE WITH RING SIDEROBLASTS USING AKTIVIN ACTRLL LIGAND TRAPS |
| AU2020316632B2 (en) | 2019-07-19 | 2025-09-18 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (TDT) |
| CN112924684B (zh) * | 2019-12-05 | 2022-07-29 | 中国科学院大连化学物理研究所 | 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒 |
| CA3176735A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CN115427056A (zh) * | 2020-04-13 | 2022-12-02 | 细胞基因公司 | 使用actriib配体陷阱和菲卓替尼治疗贫血的方法 |
| EP4142769A4 (en) | 2020-04-28 | 2024-05-15 | Acceleron Pharma Inc. | ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| WO2022098877A1 (en) * | 2020-11-06 | 2022-05-12 | Acceleron Pharma Inc. | Formulations comprising actrii polypeptide variants |
| WO2022150590A1 (en) * | 2021-01-08 | 2022-07-14 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| JP2024504349A (ja) | 2021-01-20 | 2024-01-31 | ビフォー （インターナショナル） エージー | 骨髄異形成症候群（ｍｄｓ）の処置において使用するためのフェロポーチン阻害剤 |
| EP4731218A1 (en) | 2023-06-26 | 2026-04-29 | Vifor (International) AG | Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh) |
| WO2025122830A1 (en) * | 2023-12-08 | 2025-06-12 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii signaling inhibitors |
| WO2026041650A1 (en) | 2024-08-20 | 2026-02-26 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of lupus nephritis |
| WO2026096847A1 (en) * | 2024-11-01 | 2026-05-07 | Bristol-Myers Squibb Company | Methods of regulating inflammation and autophagy using actriib ligand traps |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4247A (en) * | 1845-11-01 | Jordan l | ||
| US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| WO2008076437A2 (en) * | 2006-12-18 | 2008-06-26 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| CN102131822A (zh) * | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| TWI626945B (zh) * | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| JP6211767B2 (ja) * | 2009-09-09 | 2017-10-11 | アクセルロン ファーマ， インコーポレイテッド | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| KR20140084211A (ko) * | 2011-10-17 | 2014-07-04 | 악셀레론 파마 인코포레이티드 | 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물 |
| EP2830642B1 (en) * | 2012-03-30 | 2019-08-28 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of iduronate- 2-sulfatase |
| CA2889286A1 (en) * | 2012-10-24 | 2014-05-01 | Celgene Corporation | Methods for treating anemia |
| EP2912462B1 (en) * | 2012-10-24 | 2019-08-07 | Celgene Corporation | Biomarker for use in treating anemia |
| AU2013352156B2 (en) * | 2012-11-27 | 2018-12-06 | Children's Medical Center Corporation | Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction |
-
2016
- 2016-05-12 JP JP2017559025A patent/JP6976859B2/ja not_active Expired - Fee Related
- 2016-05-12 TW TW110148304A patent/TWI814187B/zh active
- 2016-05-12 MY MYPI2017704290A patent/MY189601A/en unknown
- 2016-05-12 TN TNP/2017/000468A patent/TN2017000468A1/en unknown
- 2016-05-12 TW TW105114763A patent/TWI762444B/zh active
- 2016-05-12 CN CN201680041002.2A patent/CN107847562A/zh active Pending
- 2016-05-12 US US15/573,177 patent/US20180125928A1/en not_active Abandoned
- 2016-05-12 KR KR1020177035838A patent/KR102640198B1/ko active Active
- 2016-05-12 AU AU2016261913A patent/AU2016261913B2/en active Active
- 2016-05-12 HK HK18110608.3A patent/HK1251157A1/zh unknown
- 2016-05-12 IL IL284686A patent/IL284686B2/en unknown
- 2016-05-12 EP EP16793499.1A patent/EP3294320A4/en active Pending
- 2016-05-12 CA CA2985777A patent/CA2985777A1/en active Pending
- 2016-05-12 WO PCT/US2016/031999 patent/WO2016183280A1/en not_active Ceased
- 2016-05-12 JO JOP/2016/0092A patent/JOP20160092B1/ar active
-
2017
- 2017-11-08 IL IL255527A patent/IL255527B/en unknown
- 2017-11-16 PH PH12017502079A patent/PH12017502079A1/en unknown
-
2021
- 2021-08-13 JP JP2021131870A patent/JP2021191755A/ja active Pending
- 2021-10-29 AU AU2021258087A patent/AU2021258087B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI658834B (zh) | 用於治療或預防ｃ５相關疾病的醫藥組合物以及治療或預防ｃ５相關疾病的方法 | |
| TWI754622B (zh) | Ctla4結合劑 | |
| JP2024009946A (ja) | 抗ｐｄ－１抗体と他の抗体の組み合わせを含む組成物 | |
| HRP20230504T1 (hr) | Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma | |
| JP6672533B1 (ja) | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 | |
| KR20190044673A (ko) | 응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법 | |
| CA3118415A1 (en) | Tgf-.beta. receptor fusion protein pharmaceutical composition and use thereof | |
| JP2016527286A5 (enExample) | ||
| WO2023023345A2 (en) | Methods of using activin receptor type ii signaling inhibitors | |
| US10471142B2 (en) | Combination therapy using immunoglobulin and C1-Inhibitor | |
| RU2017111228A (ru) | Композиции антитела против IL-7R | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| TW202222823A (zh) | 投與治療劑量的雙特異性ｔ細胞接合分子治療癌症之方法 | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| JP2017524675A5 (enExample) | ||
| WO2020243603A1 (en) | Dosing of bispecific t cell engager | |
| JP7842532B2 (ja) | 再生不良性貧血を治療するための医薬組成物 | |
| Ochi et al. | Bispecific antibodies for multiple myeloma: past, present and future | |
| JP2024527180A5 (enExample) | ||
| WO2025184284A1 (en) | Methods of using activin receptor type ii signaling inhibitors | |
| NZ737043B2 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| TW201828984A (zh) | 使用介白素-17(il-17)拮抗劑治療痤瘡的方法 | |
| NZ737043A (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| WO2026040955A1 (zh) | 双特异性抗cd3/cd20多肽复合物的用途 | |
| Lindfelt | Drugs that act on the immune system: cytokines and monoclonal antibodies |